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Maternal anxiety during pregnancy is associated with adverse fetal, neonatal, and child 
outcomes, but biological mechanisms remain unclear. Altered fetal DNA methylation 
(DNAm) has been proposed as a potential underlying mechanism. In the current study, 
we performed a meta-analysis to examine the associations between maternal anxiety, 
measured prospectively during pregnancy, and genome-wide DNAm from umbilical 
cord blood. Sixteen non-overlapping cohorts from 12 independent longitudinal studies 
of the Pregnancy And Childhood Epigenetics Consortium participated, resulting in a 
combined dataset of 7 243 mother-child dyads. We examined prenatal anxiety in relation 
to genome-wide DNAm and differentially methylated regions. We observed no 
association between the general symptoms of anxiety during pregnancy or pregnancy-
related anxiety, and DNAm at any of the CpG sites, after multiple-testing correction. 
Further, we identify no differentially methylated regions associated with maternal 
anxiety. At the cohort-level, of the 21 associations observed in individual cohorts, none 
replicated consistently in the other cohorts. In conclusion, contrary to some previous 
studies proposing cord blood DNAm as a promising potential mechanism explaining the 
link between maternal anxiety during pregnancy and adverse outcomes in offspring, we 
found no consistent evidence for any robust associations between maternal anxiety and 
DNAm in cord blood. Larger studies and analysis of DNAm in other tissues may be 
needed to establish subtle or subgroup-specific associations between maternal anxiety 






Anxiety symptoms during pregnancy are common, and an estimated 15% of pregnant 
women fulfill the diagnostic criteria of any anxiety disorder.1 Perinatal anxiety may not 
only affect the mother, but could also have long-lasting implications for the offspring. 
Children of mothers with high levels of prenatal anxiety are more likely to be preterm 
and small-for-gestational-age, and to have emotional and behavioral problems that may 
persist beyond childhood.2–4  
The biological pathways underlying maternal mental health during pregnancy and 
offspring development are poorly understood. One proposed pathway is fetal 
programming through epigenetic modifications: prenatal stressors may alter fetal DNA 
methylation (DNAm), which may affect downstream gene expression, neuroendocrine 
functioning, and behavioral development.5 Several animal studies have supported this 
hypothesis.5 However, human evidence of associations between maternal anxiety during 
pregnancy and offspring DNAm is mixed and mostly based on small samples.6 A recent 
epigenome-wide association study (EWAS) found that high levels of prenatal anxiety 
predicted differential DNAm at 13 CpG sites in cord blood (N=445), but these findings 
did not replicate in another sample (N=969).14  
We present a meta-analysis of epigenome-wide associations between prenatal general- 
and pregnancy-related anxiety and cord blood DNAm, from 12 independent longitudinal 
studies (total N=7,243).  
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MATERIALS AND METHODS 
Participating studies 
Sixteen cohorts from 12 independent longitudinal studies, in the Pregnancy And 
Childhood Epigenetics Consortium (PACE),15 participated in this meta-analysis. These 
were the 1) Avon Longitudinal Study of Parents and Children (ALSPAC) (United 
Kingdom),16 2) Born in Bradford (BiB) (United Kingdom),17 subdivided into South 
Asian (BiB-1) and European (BiB-2) cohorts, 3) Drakenstein Child Health Study 
(DCHS) (South Africa),18 comprising the DCHS-450k and DCHS-EPIC cohorts, 
differentiated by the choice of DNAm array (Illumina 450k and EPIC, respectively), 4) 
EDEN Mother-Child Cohort (EDEN) (France),19 5) Generation R Study (Generation R) 
(Netherlands),20 6) Genome-Wide Population-based Association Study of Extremely 
Overweight Young Adults (GOYA) (Denmark; weight distribution of the subsample 
used for these analyses corresponds to the general population),21 7) INfancia y Medio 
Ambiente (INMA) (Spain),22 8) Norwegian Mother, Father and Child Cohort Study 
(MoBa) (Norway),23 comprising the MoBa-1 and the MoBa-2 cohorts, two independent 
samples from the MoBa study, 9) Prediction and Prevention of Preeclampsia and 
Intrauterine Growth Restriction study (PREDO) (Finland),24 comprising the PREDO-
450k and the PREDO-EPIC cohort, differentiated by Illumina 450k vs EPIC DNAm 
array, respectively, 10) Programming Research in Obesity, Growth, Environment and 
Social Stressors study (PROGRESS) (Mexico),25 11) PRogramming of 
Intergenerational Stress Mechanisms study (PRISM) (USA),26 and 12) Project Viva 
(Viva) (USA).27  




Exposure: Maternal anxiety during pregnancy 
Anxiety can be assessed using general self-report instruments or instruments 
specifically designed for pregnant women, which may be more predictive of perinatal 
outcomes and include pregnancy-related items such as childbirth-related worries.28 We 
examined the two separately: we refer to anxiety symptoms measured using general 
instruments as general anxiety (not to be confused with generalized anxiety disorder), 
and pregnancy-related anxiety symptoms measured using pregnancy-specific 
instruments as pregnancy-related anxiety. In one cohort (INMA), mothers reported, 
during prenatal interviews, if a physician had diagnosed them with any anxiety disorder: 
we included INMA in the primary meta-analysis of general anxiety (Table 1). 
Instruments are described in Supplementary methods. 
Each cohort dichotomized questionnaire scores, contrasting the highest-scoring 15% of 
mothers ("high-anxiety" group), against other mothers.1,4 Scores were neither 
transformed nor standardized. In sensitivity analyses, we used continuous questionnaire 
scores (winsorized at +/- 3SD): higher scores reflect more symptoms. Cohorts with 
repeated measures of anxiety during pregnancy calculated mean scores (Table 1). 
Outcome: DNAm measurements 
Newborn umbilical cord blood DNAm was assessed with the Illumina® 
HumanMethylation450 (450k) or HumanMethylationEPIC (EPIC) BeadChip assay at 
Illumina or cohort-specific laboratories. Cohorts performed sample processing, quality 
control and normalization as described in Supplementary methods.  
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We used normalized, untransformed beta values, ranging from 0 (completely 
unmethylated) to 1 (completely methylated), after trimming extreme outliers 
(3×interquartile range from the quartile limit). 
We excluded probes mapped to X/Y chromosomes, polymorphic CpGs (overlapping 
with known single-nucleotide-polymorphisms [SNPs]),29 control or cross-reactive 
probes (targeting repetitive sequences/co-hybridizing to alternate sequences).30,31   
Function-related information was derived from GeneCards and GWAS Catalog 
(https://www.genecards.org; https://www.ebi.ac.uk/gwas, accessed August 17th, 2020). 
Covariates 
Based on theoretical expectations,3 we adjusted for child sex, maternal age, 
socioeconomic status (SES, maternal education/family income), cell counts, 
ethnicity/ancestry (if applicable) and technical covariates (e.g. batch) (Supplementary 
methods). We used reference-based projection/quadratic programming to estimate cell 
type proportions:32,33 EDEN used the Houseman reference panel,32 PRISM a combined 
panel,33,34 and others the Bakulski panel.33  
In a sensitivity analysis, we added the maternal smoking covariate. This was a separate 
model because causal associations between smoking and anxiety could be bidirectional 
and smoking could mediate some effects on DNAm (Supplementary methods). 
Statistical analyses  
Cohort-specific EWAS 
Cohort-level EWASes were performed according to a predefined analysis plan. We used 
robust multiple linear regression (rlm; MASS R-package) to control for potential 
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heteroscedasticity and influential DNAm outliers. We included participants with 
complete information. Cohorts excluded known chromosomal abnormalities, multiple 
births, and one random sibling per sibling pair. Models are described in Supplementary 
methods. 
Primary meta-analysis 
We examined associations between maternal general anxiety during pregnancy and 
DNAm at 364,659 CpG sites across 15 cohorts (ALSPAC, BiB-1, BiB-2, DCHS-450k, 
DCHS-EPIC, EDEN, Generation R, GOYA, INMA, MoBa-1, MoBa-2, PREDO-450k, 
PREDO-EPIC, PRISM, PROGRESS). We combined 450k and EPIC data and only 
included sites that are available on the 450k. We performed a sample-size-weighted 
meta-analysis using R 3.6.1 (https://www.r-project.org/) and METAL (version released 
2018-08-28),35 choosing the sample-size-weighted approach because of variation across 
anxiety scales in different cohorts. Probes were annotated using meffil (hg19/b37).29  
To assess epigenome-wide statistical inflation, we calculated cohort- and meta-analysis-
level genomic inflation factor lambdas (λ) and examined quantile-quantile plots. 
Cohort-level results were meta-analyzed at Erasmus MC; a shadow meta-analysis was 
conducted independently at the University of Helsinki.  
Secondary meta-analyses  
We performed two secondary meta-analyses. First, we examined associations between 
pregnancy-related anxiety and DNAm (Generation R, PRISM, PROGRESS, Viva); 
second, associations between general anxiety and DNAm at the 439,294 EPIC-assay-




All reported p-values are two-sided. For multiple-testing correction, we used 
Bonferroni-correction based on the number of probes (primary meta-analysis cut-off 
p<1.37×10-7). Additionally, we examined our results using the Benjamini Hochberg 
False-Discovery-Rate method (FDR).36 When we observed no statistically significant 
associations, we used a suggestive p-value threshold (p<5×10-5) to select CpGs for 
follow-up analyses. 
Sensitivity analyses  
We repeated the primary and secondary meta-analyses twice: first, adding smoking into 
covariates, and second, modelling anxiety as continuous. To address potential across-
study heterogeneity, we examined I2 statistics, and repeated the primary meta-analysis 
only including cohorts with 1) 450k or 2) EPIC array, 3) predominantly European-
ancestry cohorts (ALSPAC, BiB-2, EDEN, Generation R, GOYA, INMA, MoBa, 
PREDO), and 4) cohorts using the Bakulski panel for cell type correction.33  
We identified the 30 probes with the largest effect estimates for general anxiety in the 
three largest cohorts (Generation R, MoBa-1, ALSPAC; 10 probes/cohort), and 
examined whether effects were consistent across cohorts. This was repeated with 
pregnancy-related anxiety (largest cohorts: Generation R, Viva, PROGRESS). 
DMR analysis  
To identify differentially methylated regions (DMRs), we used dmrff:37 it addresses the 
correlation structure of DNAm and can be used to identify DMRs at the meta-analytic 
level. Ten cohorts (ALSPAC, EDEN, GOYA, Generation R, INMA, MoBa-1, PREDO-
450k, PREDO-EPIC, PRISM, PROGRESS) calculated correlations between each CpG 
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and the next 20 CpGs downstream. We used data on CpGs covered by 450k. We 
identified candidate regions: sets of nearby CpG sites (≤500bp between consecutive 
sites) that associated with anxiety (nominal p-values<0.05 in cohort-level EWAS, effect 
estimates in the same direction), and, using an extension of inverse-variance weighted 
meta-analysis, calculated the dmrff statistics. We then meta-analyzed those statistics by 
selecting sub-regions with the most extreme meta-analysis statistic. P-values for 
candidate regions were Bonferroni-corrected.  
Blood-brain comparisons 
To examine correlation between blood and brain DNAm levels at CpG sites with meta-
analytical p<5×10-5, we used two tools. The first by Hannon et al38 reports correlations 
between DNAm in blood vs prefrontal cortex, entorhinal cortex, superior temporal 
gyrus, and cerebellum. Secondly, BECon shows correlations between DNAm in blood 
vs parietal, anterior prefrontal, and ventral temporal cortex (Brodmann 7, 10, 20, 
respectively).39  
Code and data availability and ethical statements 
All studies acquired approval from local ethics committees and informed consent from 
participants. Site-level meta-analytical results are publicly available 
(https://doi.org/10.5281/zenodo.4147817). For access to cohort-level data, requests can 





Table 2 describes our 7,243 mother-child dyads. Supplementary Table 1 shows 
characteristics stratified by low-vs-high anxiety. 
General anxiety during pregnancy and DNAm 
We observed no associations between maternal general anxiety during pregnancy and 
DNAm of 364,659 CpG sites in cord blood, among 6,686 mother-child dyads, when 
using Bonferroni correction (p<1.37×10-7) (Figure 1A). We found no evidence of 
genomic inflation (λ=0.96, quantile-quantile plot in Figure 1B). 
In Table 3, we list the 15 CpG sites that were most strongly associated (p<5×10-5) with 
maternal general anxiety during pregnancy. Figure 2 shows a regression coefficient 
forest-plot at these 15 CpG sites across cohorts: effect direction was not consistent 
across cohorts for any of these sites.  
Secondary meta-analyses 
Pregnancy-related anxiety 
We found no association between pregnancy-related anxiety and DNAm among the 
2,089 mother-child dyads in four cohorts with available data (Figure SF1, λ=0.92). 
Figure SF2 shows the 8 CpG sites that were most strongly associated (p<5×10-5) with 
pregnancy-related anxiety and the variation in estimates across cohorts . At two of these 
sites (cg18769357, cg03985478), all four cohorts reported the association in the same 
direction: for cg18769357, these associations were only nominally significant (p<0.05) 
in Generation R and PRISM; for cg03985478, they were only nominally significant in 
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Generation R. Only one site, cg02624770, had a nominally significant association with 
pregnancy-related anxiety across the three largest cohorts (N>200): the direction was 
negative suggesting hypomethylation. None of the sites most strongly associated 
(p<5×10-5) with pregnancy-related anxiety overlapped with the sites most strongly 
associated (p<5×10-5) with general anxiety (Supplementary Table 2).  
EPIC-only sites 
We found no association between general anxiety during pregnancy and DNAm at the 
439,294 CpG sites that are included only on the EPIC array among 1,221 mother-child 
dyads from four cohorts (Figure SF3, λ=1.02). Figure SF4 shows all 40 EPIC-only 
sites that were most strongly (p<5×10-5) associated with general anxiety. We identified 
26 sites where general anxiety during pregnancy associated with hypermethylation 
across all four cohorts, and 3 sites where it associated with hypomethylation. (Figure 
SF4). Five sites (cg02306798, cg20639127, cg20817245, cg21202789, cg22566694) 
had a nominally significant (p<0.05) association in the same direction (all positive) with 
general anxiety across the three largest cohorts (N>200) (Figure SF4). 
FDR  
We additionally applied the FDR instead of Bonferroni method to correct for multiple 
testing. We identified no associations passing this more lenient threshold in the primary, 
nor the secondary meta-analyses.  
Sensitivity analyses 
We examined results after cohorts additionally adjusted for maternal smoking during 
pregnancy (all cohorts), or when treating the exposure as continuous (available in 14 
cohorts, maximum N=6,350) and identified no associations between general or 
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pregnancy-related anxiety and DNAm at any of the 450k or EPIC-assay sites (corrected 
for multiple testing). 
We repeated the primary meta-analysis in cohorts with 1) 450k (maximum N=5,345), 
2) EPIC (maximum N=1,341), 3) predominantly European participants (maximum 
N=5,581), and 4) Bakulski panel33 (N=6,380). Again, no associations were observed.  
Figure SF5 illustrates associations between DNAm and general (panel A) and 
pregnancy-related (B) anxiety, for 30 probes with the largest effect estimates in the 
largest cohorts. We found no consistent associations across cohorts at these sites.  
 
DMR analysis 
We identified no DMRs associated with general/pregnancy-related anxiety (after 
Bonferroni correction) (Supplementary Table 3).  
Blood-brain comparisons 
Among CpGs closest to statistical significance, none showed consistent, wide-spread 
correlations between blood and brain DNAm.  
Figure SF6 shows that two of the 15 sites most strongly associated (p<5×10-5) with 
general anxiety (cg13516541, cg01987516) exhibited a relatively concordant DNAm 
pattern (r>0.41, p<0.001) across blood vs the prefrontal cortex and superior temporal 
gyrus.38 Two of the 8 sites most strongly associated with pregnancy-related anxiety 
(cg01093369, cg03985478) showed high correlation between blood vs brain DNAm 
(r>0.44, p<0.001).38 
Figure SF7 shows that among the sites most strongly related to general anxiety, one 
(cg14776033) showed moderate negative correlations between blood and the brain 
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regions using BECon (r=-0.51…-0.31).39 One site among those most strongly associated 
with pregnancy-related anxiety (cg14200609) showed moderate negative correlations 
between blood and all brain regions (r=-0.53…-0.26). 
Sites of interest: look-up 
Supplementary Table 4 shows meta-analytical results for CpGs associated with 
maternal anxiety/depression in a previous EWAS,40 and CpGs annotated to genes of 
interest for perinatal mental health epigenetics (NR3C1, NR3C2, FKBP5, HSD11B2, 
OXTR).e.g. 6,13,41 None were consistently associated with maternal anxiety in our meta-
analysis (non-corrected p-values>0.001, inconsistent direction of effects). 
Cohort-level results 
Supplementary Table 5 shows lambdas and Bonferroni-corrected cohort-level hits. At 
genome-wide level, we observed 12 significant cohort-level associations between 
maternal general anxiety and DNAm. Five of these sites map to genes associated with 
neurodevelopmental/mental health-related phenotypes (cg06113534/DSCC1, 
cg06861562/C5orf43, cg15475427/BMP8A, cg19614454/REPS1, 
cg12670525/PARP6), however none of the 12 cohort-level hits overlapped across two 
or more cohorts, nor was the effect direction consistent across all cohorts for any of 
these sites. 
We found 9 cohort-level associations between pregnancy-related anxiety and DNAm 
(Supplementary Table 5). At only one of these sites, cg19660243, effect estimates 
were in the same direction (positive) in all cohorts. Two sites mapped to genes 
previously linked to neurodevelopmental/mental health phenotypes 
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(cg11920519/MAP1LC3A, cg15401317/NARS2), but showed no consistent pattern of 
findings across cohorts.  
We advise a very cautious interpretation of these 21 cohort-level associations. They are 
likely false positives, given the lack of consistency across cohorts. 
DISCUSSION 
We found no robust evidence of associations between cord blood DNAm and either 
general symptoms of anxiety during pregnancy or pregnancy-related anxiety across 16 
non-overlapping cohorts within 12 independent longitudinal studies. These results were 
consistently supported by a comprehensive set of additional analyses.  
We dichotomized exposures to address different questionnaire score distributions, 
harmonize questionnaire-based with diagnosis-based measures, and define a subgroup 
of interest across a continuum of symptom severity. The 15% cut-off was validated 
against diagnostic interviews in our largest cohort,4 and is in line with estimated global 
prevalence of prenatal anxiety disorders (~15%),1 and previous studies in non-clinical 
populations.42,43 Nonetheless, by modelling anxiety with a dichotomous approach, we 
inevitably lose information and power. Thus, we also examined anxiety symptoms as 
continuous scores (excluding INMA, for which only a binary diagnosis was available). 
Consistent with our main results, these analyses revealed no associations between 
anxiety and DNAm.  
DNAm at nearby sites is correlated, and there is disagreement over the optimal method 
of genome-wide correction. We confirmed our findings using FDR and Bonferroni 
methods. No meta-analytical associations would survive correction for multiple testing 
even if we used a more lenient 450k-array P-value cut-off (2.4×10-7).44 Removal of 
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invariable probes could reduce the number of tests. However, invariable probes differ 
per tissue and we are not aware of a cord-blood-specific reference list. Our results would 
not change if we filtered out across-tissue invariable probes (n=42,315).45 We show the 
meta-analytic results for sites closest to the Bonferroni threshold, to facilitate evaluating 
across-cohort consistency. To further address non-independence between CpGs, we 
searched for DMRs and found none. Finally, we uploaded the meta-analytical results 
for all probes in a public repository, to enable others to examine specific sites or apply 
future filtering methods. 
We combined data from different countries and different arrays. Overall DNAm patterns 
are, however, highly correlated between the 450k and EPIC arrays.46 Sensitivity 
analyses did not suggest that array differences would represent a source of substantial 
bias. Similarly, we ran sensitivity analyses including only the predominantly European 
cohorts to address potential issues arising from ethnic variation. The results were 
unchanged.  
These findings are in line with some,7,14 but not all previous studies.8–10,12,13 One 
epigenome-wide study used Viva (N=445) as a discovery and Generation R (N=969) as 
a replication sample (both studies included in this meta-analysis),14 while others relied 
on smaller samples from individual cohorts (N=45-576).  
A possible interpretation of our results is that maternal symptoms of anxiety may not 
substantially affect circulating fetal DNAm, and the associations between prenatal 
anxiety and child phenotypes that have been observed in several studies2,3 are explained 
by other mechanistic pathways. These could include, for example, the postnatal 
extension of maternal anxiety and subsequent differences in parenting and the home 
environment, increased risk of perinatal complications/interventions, or confounding by 
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genetic and environmental risk factors which could affect both anxiety and child 
outcomes. Anxiety may also impact methylation in specific target tissues only without 
reflection of these changes in blood.  
Alternative interpretations may be considered in light of our study limitations. First, 
maternal anxiety may associate with cord blood DNAm, but the effects at individual 
sites could be so subtle that using the current methods, they could not be detected. With 
>7,000 mother-child dyads, our study is substantially larger than previous studies,11,14 
and meta-analyses of similar/smaller samples have shown robust associations between 
cord blood DNAm and other prenatal exposures such as maternal smoking,47 however 
we may have insufficient power to detect all meaningful change in DNAm. DNAm 
variation is site-specific, and while some evidence has suggested associations between 
cord blood DNAm and child neurodevelopmental outcomes,48 more information about 
the magnitude of associations between cord blood DNAm and relevant child phenotypes 
is needed before deciding what constitutes a meaningful change in DNAm. In particular, 
analyses of pregnancy-related anxiety were based on a smaller sample and could be 
underpowered. Although we observed no meta-analytic association between pregnancy-
related anxiety and cord blood DNAm, some CpGs exhibited nominal-level associations 
with pregnancy-related anxiety in the largest cohorts. Similarly, we report some nominal 
associations between general anxiety and DNAm at sites included only on the EPIC 
array across the largest cohorts. These could be of interest for future studies.  
Second, there may be subgroup-specific associations between maternal anxiety and 
DNAm that merit future research. Effects specific to most severe or certain types of 
anxiety could go unnoticed in our population-based cohorts due to rarity/selective 
attrition. We lacked power to examine trait-anxiety as a separate construct49 or effects 
mediated by medication. Furthermore, measurement error and variation across cohorts 
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in the timing and instrument used to measure anxiety likely contributed to reduced 
power. However, questionnaires were chosen per cohort to reliably measure anxiety 
within the specific population, and it is unlikely that instrument differences would hide 
robust, wide-spread associations between anxiety and DNAm. Most scales were 
previously validated in perinatal settings.e.g. 4,28,50–52 For example, GHQ, BSI, and STAI 
were validated against perinatal diagnostic interviews,4,50 and CCEI correlates highly 
with STAI-S/STAI-T during pregnancy (r=.70/r=.76, respectively)52 (Supplementary 
Methods contains more psychometric information). Further, we examined pregnancy-
related anxiety separately as recommended.28 Nonetheless, some symptom- or disorder-
specific effects may have gone unnoticed. Further, we encourage research into potential 
sex differences. We included sex as a covariate but did not examine sex-specificity, to 
limit the number of tests to those with the most power. 
Our choice to focus on anxiety alone may be considered another limitation. For example, 
we did not examine comorbidity between anxiety and depression, which is common and 
could increase the risk for poor perinatal outcomes compared to anxiety alone.53 We 
encourage research on related prenatal exposures, including depression, stressful events, 
and substance use disorder, for which the existing small epigenetic studies have shown 
mixed results. e.g. 14,54 
Finally, emerging cell-type correction methods could prove useful. However, we used 
a validated approach to address cell composition, and 14 of 16 cohorts used the same 
reference panel.33 A study assessing prenatal phthalate exposure and cord blood DNAm 
found only small differences when three different cell-type reference panels were 
used.55 Also, no significant results emerged in analyses only including cohorts with the 




Our study has several strengths. Firstly, the collaboration across studies allowed us to 
examine the association between maternal anxiety and cord blood DNAm among 
>7,000 mother-child dyads. Secondly, we examined pregnancy-related anxiety, which 
may be more closely associated with perinatal outcomes, compared to general anxiety 
symptoms.28 Thirdly, combining data from several cohorts with the EPIC array, we 
examined DNAm across hundreds of thousands of sites that have not been examined 
before, in particular increasing coverage of regulatory regions. Our null findings do not 
definitely refute a link between prenatal anxiety and epigenetic programming. Future 
studies of other tissues of interest, such as the brain and the placenta, and less well-
understood forms of epigenetic alterations, such as histone modifications, could prove 
relevant. Also, studies with larger samples and higher resolution could elucidate subtle 
effects.  
Conclusions: This meta-analysis suggests little evidence of a relation between maternal 
anxiety during pregnancy and differential DNAm in cord blood. While this is a 
considerably large study on maternal mental health and offspring DNAm, even larger 
studies with validated clinical diagnoses instead of self-reported symptoms may be 
needed to establish subtle or subgroup-specific associations between maternal anxiety 
and the fetal epigenome. Other tissues, epigenetic mechanisms, and aspects of perinatal 
mental health warrant exploration, as we begin to disentangle the many biological 
mechanisms that could explain how perinatal maternal mental health affects the next 
generation. 
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Figure 1. Manhattan and quantile-quantile plot showing meta-analytic 
associations between general anxiety during pregnancy and cord blood DNA 
methylation (within 15 cohorts, maximum N=6 686 mother-child dyads) 
Panel A. Manhattan plot (red line indicates the Bonferroni threshold) 
Panel B. Quantile-quantile plot (λ=0.962) 
Figure 2. Forest plot showing associations between general anxiety during 
pregnancy and cord blood DNA methylation for the most significant associations 
(p<5×10-5), across all cohorts with available data, in order of sample size. 
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